Oncology Pipeline Surge Through 2026-2027 Drives Biotech Valuations as Novel Mechanisms Target NSCLC
Multiple oncology drug candidates are advancing toward FDA approval in 2026-2027, with concentrated activity in non-small cell lung cancer therapeutics. Novel approaches including antibody-drug conjugates, targeted radiopharmaceuticals, and immune checkpoint inhibitors represent critical inflection points for biotechnology valuations. Regeneron's strategic entry into radiopharmaceuticals and clinical progress from emerging biotechs signal investor confidence in pipeline strength.
Salvado•